Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

New Guidelines Establish Recommendations for HER2 Testing for GEA

November 21st 2016

An expert panel has issued a set of guidelines for patients with gastroesophageal adenocarcinoma, recommending that they be tested for HER2 status before initiation of targeted therapy.

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

November 19th 2016

Biomarker Development Key to Optimizing Immunotherapy in Lung Cancer

November 17th 2016

The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC

November 13th 2016

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

Graham Mann on Genetic Mutations in Different Types of Melanoma

November 9th 2016

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

IDO Inhibitors for Melanoma

October 31st 2016

Emerging Immunotherapy Combinations for Melanoma

October 31st 2016

Looking to the Future of Melanoma

October 31st 2016

Sequencing Strategies for Recurrent/Refractory Melanoma

October 31st 2016

Treatment Beyond Melanoma Progression

October 31st 2016

Abscopal Effect and Pseudoprogression in Melanoma

October 31st 2016

Single vs Dual Checkpoint Inhibition in Melanoma

October 31st 2016

Questions About Sequencing in BRAF-Mutant Melanoma

October 31st 2016

Dual-Targeted Therapy for BRAF-Mutant Melanoma

October 31st 2016

Risk Stratification for Advanced Melanoma

October 31st 2016

Neoadjuvant Therapy for Melanoma

October 31st 2016

Adjuvant PD-(L)1 Inhibitors for Melanoma

October 31st 2016

Adjuvant Therapy for Melanoma

October 31st 2016